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Background: The detection of early warning signs is essential in the long-term treatment of bipolar disorders.
However, in bipolar patients’ daily life and outpatient treatment the assessment of upcoming state changes faces
several difficulties. In this trial, we examine the effectiveness of a smartphone based automated feedback about
ambulatory assessed early warning signs in prolonging states of euthymia and therefore preventing hospitalization.
This study aims to assess, whether patients experience longer episodes of euthymia, when their treating psychiatrists
receive automated feedback about changes in communication and activity. With this additional information an
intervention at an earlier stage in the development of mania or depression could be facilitated. We expect that the
amount of time will be longer between affective episodes in the intervention group.
Methods/design: The current study is designed as a randomized, multi-center, observer-blind, active-control, parallel
group trial within a nationwide research project on the topic of innovative methods for diagnostics, prevention and
interventions of bipolar disorders. One hundred and twenty patients with bipolar disorder will be randomly assigned to
(1) the experimental group with included automated feedback or (2) the control group without feedback. During the
intervention phase, the psychopathologic state of all participants is assessed every four weeks over 18 months. Kaplan-
Meier estimators will be used for estimating the survival functions, a Log-Rank test will be used to formally compare
time to a new episode across treatment groups. An intention-to-treat analysis will include data from all randomized
patients.
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Discussion: This article describes the design of a clinical trial investigating the effectiveness of a smartphone-based
feedback loop. This feedback loop is meant to elicit early interventions at the detection of warning signs for the
prevention of affective episodes in bipolar patients. This approach will hopefully improve the chances of a timely
intervention helping patients to keep a balanced mood for longer periods of time. In detail, if our hypothesis can be
confirmed, clinical practice treating psychiatrists will be enabled to react quickly when changes are automatically
detected. Therefore, outpatients would receive an even more individually tailored treatment concerning time and
frequency of doctor’s appointments.
Trial registration: ClinicalTrials.gov: NCT02782910: Title: “Smartphone-based Ambulatory Assessment of Early Warning
Signs (BipoLife_A3)”. Registered May 25 2016.
Protocol Amendment Number: 03. Issue Date: 26 March 2018. Author(s): ES.
Keywords: Bipolar disorder, Ambulatory assessment, Prevention, Early warning signsBackground
Bipolar disorder as an affective illness with chronic fea-
tures shows a very diverse and often unpredictable course
of illness concerning the number, length and frequency of
recurrent depressive and (hypo) manic states [1]. This
condition causes high costs both from an individual as
well as from a societal point of view [2]. Patients with bi-
polar disorder suffer from marked impairment in everyday
social and occupational life, e.g. experiencing a diminished
quality of life, often due to lower levels of psychosocial
functioning [3, 4]. Furthermore, outpatient and inpatient
treatment of affective episodes leads to high health care
costs. Necessary reductions of working hours, higher ab-
senteeism or premature pension are common and cause
substantial secondary economic costs [5, 6].
Though not yet proven the detection of early warning
signs (EWS) is considered to improve the course of bipolar
illness [7] but it is mainly the patient’s own responsibility
as he or she is usually seen by the treating psychiatrist once
every few weeks or even months, especially when euthy-
mic. Mood charting as the common tool for EWS detec-
tion has several limitations in clinical practice. Firstly, even
if done on a daily basis, mood-charting as retrospective
and subjective self-assessment, is generally prone to be af-
fected or biased by heuristics, cognitive impairment and
symptoms of an evolving episode [8, 9]. Also, demographic
characteristics may interfere with the person’s capacity to
precisely report the items of interest [10]. Furthermore, the
frequency of recording mood, sleep and medication intake
reduces over time as many patients with bipolar dis-
order get tired of mood charting, especially in long
episodes of euthymia. However, as the course of bipo-
lar illness remains highly unpredictable even after long
periods of euthymia, the cessation of mood charting
may turn out to be detrimental [11].
To overcome the outlined problems, ambulatory mon-
itoring has recently been implemented in the long-term
treatment of bipolar disorders. This approach is benefi-
cial as it delivers objective, real-time and real-life data inan instant. As a result, much research has been accumu-
lated over the past couple of years employing new tech-
nologies [12–18]. Software-based mood charting using
the ChronoRecord software is advantageous compared
to paper-pencil methods regarding data storage and legi-
bility. This has been validated both for depressive and
manic symptoms in bipolar patients [12, 13]. To the best
of our knowledge, there are published results of only one
clinical trial using smartphones to predict and prevent up-
coming episodes. This preliminary single-blind random-
ized trial studied the impact of electronic self-monitoring
of subjective and objective symptoms of bipolar disorders
on changes in affective symptoms (primary outcome) as
well as depressive and manic symptoms. It was initiated in
September 2011 and is referred to as the MONARCA trial
[14]. According to reported results of the MONARCA
trial electronic self-monitoring, via smartphone, had no
significant effect on bipolar symptomatology. For patients
in the intervention group there was even a trend of more
sustained depressive symptoms [19]. In a second trial the
researchers aimed to investigate the usefulness of auto-
mated feedback on objective and subjective smartphone
data for the reduction of affective symptoms [20]. These
results have not yet been published.
Our clinical trial is the first one in German speaking
countries to investigate the usefulness of a smartphone-
based feedback loop triggering early interventions at the
detection of warning signs for the prevention of severe
depressive and manic states in bipolar patients. The
objective of this randomized controlled trial, referred to
as the SBAA-BD study, is to assess the effectiveness of
automated feedback about continuous smartphone based
ambulatory monitoring of potential early warning signs
of upcoming depressive/(hypo) manic episodes. The
study investigates whether time to new affective epi-
sodes and following hospitalizations can be prolonged
in the intervention group. In the MONARCA I trial the
placebo group were given a cell phone without an applica-
tion to monitor the symptoms of interest. However, the
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warning signs may have an impact on the outcome(s)
in mood disorders [21]. For this reason we decided to
monitor early warning signs in the control group in an
identical fashion, by smartphone-based ambulatory
assessment including real-time data capture (SBAA).
Patients are informed about the group that they are
assigned to. Therefore within the 18 months interven-
tion phase identical ambulatory monitoring of EWS of
a depressive or (hypo) manic episode is taking place in the
control group, serving as a comparator. However the treat-
ing psychiatrist has no insight in potential deviations of
the patients’ smartphone data from his or her individually
calculated baseline data. Irrespective of group assignment,
all patients receive guideline-based, state-of-the-art main-
tenance treatment. In comparison to the MONARCA I
trial, the parameters assessed in our study originate exclu-
sively from objective data captured in real time. No event-
or time-triggered subjective data like mood or energy level
have to be entered by the participants so that the probabil-
ity of subjective and retrospective biases is expected to be
reduced and adherence to study protocol might be en-
hanced. Additionally, the possibility of worsening depres-
sive symptoms could be reduced as patients do not have
to enter their subsequent depressive symptoms every day
and process their current mental state in a negative man-
ner [19]. Additionally, patients in this trial stay enrolled for
a longer period of time (18 months) than in most of the
trials mentioned above. Additionally, we are pursuing a
larger sample with 120 randomized patients to overcome
limitations of previous work on smartphone-based object-
ive monitoring in bipolar disorder [22]. All data is auto-
matically recorded at the very moment when the behavior
(communication and activity) occurred without driving the
patients’ attention to the fact that his or her behavior is
currently monitored.
We hypothesize that the length of time to a new affective
episode and subsequently necessary hospitalization is sig-
nificantly longer in the Smartphone-Based Ambulatory
Assessment group (SBAA+). In this condition clinicians re-
ceive automated feedback about substantial change from
baseline concerning their patients’ objective smartphone
usage data (communication and activity patterns). As a
consequence they can intervene at an earlier stage in
the development of mania or depression, compared to
the Smartphone-Based Ambulatory Assessment group,
excluding personalized real-time data-driven therapeutic
interventions (SBAA).
Methods/design
Design and study setting
This study is a randomized, multi-center, rater-blinded,
active-control, parallel group trial within a nationwide
research project on the topic of innovative methods fordiagnostics, prevention and interventions of bipolar dis-
orders [23, 24]. Assessments are scheduled weekly in the
prerandomization phase (4–20 weeks) and monthly in
the intervention phase (72 weeks). End of intervention
phase is followed by a post-intervention visit after four
weeks. Five outpatient centers of psychiatric clinics at
German university hospitals (Dresden, Berlin, Hamburg-
Eppendorf, Frankfurt, Bochum), specialized in the treat-
ment of bipolar disorders will assess data for this trial.
Recruitment shortages are planned to be overcome by
opening further study sites (Neuruppin, München,
Tübingen). The coordinating site is the University
Medical Center in Dresden, supported by the Coordin-
ation Center for Clinical Trials (KKS). The clinical trial
conforms to the requirements of the MDR (Medical Device
Regulation).
Participants
Potentially eligible participants will be approached at the
participating university hospitals (outpatient clinic, in-
patient units, and day clinic) by their treating psychia-
trists. Furthermore, our study project was presented in
local print media. In addition, potential participants
could find relevant information on the trials homepage
[24]. Finally, board certified psychiatrists were provided
with the necessary information by mail as well as in the
context of continued medical education training at our
hospital. Eligible participants for this trial meet diag-
nostic criteria for Bipolar Disorders I or II and they
can be either symptomatic or asymptomatic at time of
enrollment (DSM-5: 296.4×; 296.5×; 296.89). At time
of randomization, participants have to be remitted
(DSM-5: 296.45, 296.46; 296.55, 296.56; 296.89). Fur-
ther inclusion criteria consist of (1) age > 18 years, (2)
signed informed consent prior to enrollment, (3) ≥ 3
affective episodes in last 5 years, one of them being a
(hypo) manic episode, (4) smartphone usage, (5) and
each patient must have a sufficient level of under-
standing to agree to all tasks required by the protocol.
Exclusion criteria are comprised of (1) participation in
another clinical intervention trial for the last 4 weeks
prior to enrollment, (2) substance or other disorders
that prevent the patient to understand the nature and
consequences of the clinical trial, (3) signs that the pa-
tient will probably not comply with the study protocol
(e.g. lack of cooperativeness), (4) current substance
use disorder (except for tobacco and caffeine), moder-
ate or severe, at enrollment, (5) borderline personality
disorder, antisocial personality disorder, (6) dementia,
organic brain disorders, (7) patients with a physical
illness that probably requires inpatient treatment for
more than 4 weeks per annum (exclusion: bipolar dis-
order), (8) patients working in a shift system which
does not ensure regular night sleep, (9) relatives or
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(10) women of childbearing age, excluding women
meeting the following criteria: post-menopausal, post-
operative (6 weeks after ovariectomy), regular and cor-
rect use of a contraceptive method, sexual abstinence
or vasectomy of partner, (11) pregnancy or nursing.
The study population of aim, who meet our criteria, is
representative of bipolar patients in outpatient treat-
ment. Pregnant and nursing women as well as women
who might get pregnant during the trial are excluded as
a requirement for trials conforming to the Medical Device
Regulation (MDR).
Intervention
All patients included in this study use a smartphone with
an installed application called movisensXS. MovisensXS is
an electronic e-diary software, which additionally can
track and transmit smartphone data collected from sen-
sors inside the device. Patients can decide, whether they
want to use the study smartphone (a currently available
mid-priced Samsung smartphone) or install the app via
Google Play Store on their own device. Technical require-
ments include Android version 4.0 or higher, CPU of
600 MHz or above, acceleration sensor and GPS. In this
study, the movisensXS app monitors current location via
GPS, an estimate of the covered steps (using the devices’
acceleration sensor), mobile communication parameters
(number and duration of incoming and outgoing calls,
number and length of incoming and outgoing text mes-
sages, number of different call and text contacts), usage
duration of common communication apps (e.g. What-
sApp, Facebook Messenger), number and duration of
times the display of the device is on/off, as well as rates of
transmitted and received data. For enrolled patients, a
pseudonymized electronic file is created on the movi-
sensXS platform and all data is transmitted daily to a se-
cured server. Data protection requirements are complied
with at any stage of data storage and transmission pro-
cesses. Every 24 h data are drawn from the data storage
server by a feedback server via a secure connection
and data of patients in the intervention group are com-
pared with individual baseline data performed. The
intervention-algorithm is based on a combination of
threshold values associated with parameters which are
linked to DSM-5 criteria of bipolar disorders, i.e.
change in goal-directed or non-goal directed activity
and change of communication pattern (e.g. more talk-
ative than usual). Psychomotor agitation/retardation is
operationalized by movement patterns derived from
two smartphone sensor systems. Daily travel distances in
kilometers per day are calculated via GPS coordinates. The
acceleration sensor in the smartphone tracks acceleration
in three spaces. Daily movement activity is assessed by
number of steps. General inactivity is calculated bynumbers of hours without any smartphone activity, which
includes no acceleration data, no phone calls or text
messages and the smartphones display being turned off.
Communication is operationalized by tracking the fre-
quency and length of phone calls and text messages using
the smartphone.
First, daily values are calculated for all monitored pa-
rameters. During a stabilization period (four weeks of
euthymia) in the prerandomization phase individual
baseline values (mean and standard deviation) for the
persons’ typical smartphone usage, communication and
activity behavior in the following eight parameters are
calculated: (1) travelled distance (km/day), (2) steps/day,
(3) number of outgoing calls/day, (4) average phone call
duration/day, (5) length of outgoing text messages/day, (6)
hours when smartphone is inactive, (7) frequency of display
on/day and (8) duration of display on/day. During the inter-
vention phase daily deviations of daily values from baseline
are calculated. A defined alarm threshold is exceeded when
two or more parameters exceed or fall below the 20% or
above the 80% percentile on three subsequent days. The
direction of the deviation has to be the same for each vari-
able on these three days but can differ between different
variables. For patients in the intervention group, alarms are
automatically forwarded by email to the respective study
center. The attending psychiatrist contacts the patient and
decides whether an affective episode is present or develop-
ing and carries out the next standard procedures as in usual
practice, e.g. appointing a personal contact to discuss treat-
ment options with the patient. If no affective episode is
present and the alarm is not explicable by current external
circumstances of the patients’ situation the signal is rated as
a false alarm. In this case, the alarm thresholds are raised
by 5% (values of the 20% and the 80% percentile). In case of
an undetected mood episode during the intervention phase
the thresholds will be lowered by 10%. Information flow is
depicted in Fig. 1.
To prevent false alarms during e.g. holidays or physical
illness, patients can individually pause the monitoring of
data during these episodes. For patients in the control
group, no alarms will be forwarded to the respective study
center. All patients receive guideline-based, state-of-the-art
maintenance treatment for bipolar disorder. In addition,
within the study protocol requirements the investigators
aim at giving maximum flexibility to the study participants
as to the required study appointments. To ensure patients
adherence and continued data collection in both groups,
an automated email is sent to the study center when no
smartphone activity is monitored within 24 h. In case of
continued non-adherence to study protocol, such as re-
peatedly deactivated smartphone for more than 24 h,
patients can be excluded from further participation. To im-
prove adherence, patients receive an expense allowance of
15 € per month to ensure that costs are covered for
Fig. 1 Information flow. standard information flow
feedback information flow
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study smartphone, patients can further keep the de-
vice once participation is completed following study
protocol so that changing back to another device
after study participation is excluded as a recruitment
hindrance. All patients can withdraw previously pro-
vided consent at any time without specification of
reasons and without any adverse or disadvantageous
consequences.
Measures
Diagnostic and rating scales
At screening, bipolar diagnosis is assessed with the Struc-
tured Clinical Interview for DSM Disorders (SCID-I,
German version) [25] for DSM-IV. An additional question
concerning abnormally and persistently increased activity
or energy is included to conform to current DSM-5
criteria for depressive, manic or hypomanic episodes [26].
The semi-structured interview is conducted face-to-face
and is established for diagnosing mental disorders.
Throughout the study, current affective episodes are
assessed with the SCID-I section A for affective episodes,
including the additional DSM-5 criterion described above.
Furthermore, (hypo) manic symptoms are dimensionally
rated with the Young Mania Rating Scale (YMRS) [27]
which consists of 11 items. Symptom severity is rated with
0 to 4 points; four items are double-weighted. A total
value below 12 is considered clinically insignificant. The
YMRS is regarded as gold standard in mania psychometry
and its reliability (r = .93) and validity (r = .86 to .89) are
well studied [27]. Depressive symptoms are dimensionally
rated with the Inventory of Depressive Symptomatology,
clinician version (IDS-C 30) [28] which consists of 30
items. Symptom severity is rated with 0 to 3 points. A
total value below 18 is considered clinically insignificant.
The IDS is well established in the assessment of depressivesymptom severity. Good reliability (r = .89) and validity
(r = .81) are reported for patients with bipolar disorder
[29]. All ratings will be performed by trained and expe-
rienced psychologists and/or psychiatrists and data is
directly entered in the electronic database. In addition,
source data are documented by paper and pencil and
signed by the investigator upon completion. Paper ver-
sions of all instruments used are provided in the inves-
tigator site file in case a direct entry of data should not
be possible due to technical reasons.
Outcomes
Primary outcome of this trial is time to new affective epi-
sode, defined by DSM-5 criteria for depressive, manic or
hypomanic episode. The primary outcome will be deter-
mined by SCID I section A (for DSM-IV, additional DSM-5
question for energy/activity being included), criteria for
current depressive and (hypo) manic episode, in monthly
assessments during the intervention phase. The primary
outcome is clinically highly relevant to determine the
affective and mental stability of bipolar patients.
Secondary endpoints are (1) time to a new depressive
episode, (2) time to a new (hypo) manic episode, (3)
time to a new affective episode defined by DSM-5 but
with modified time criterion of ≥ four days of episode
duration, (4) percentage of assessments during interven-
tion phase at which the original DSM-5 criteria for an
affective episode are met, (5) percentage of assessments
during intervention phase at which the modified DSM-5
criteria for an affective episode are met. These outcomes
will also be determined by SCID I section A (for DSM-IV,
additional DSM-5 question for energy/activity being in-
cluded), criteria for current depressive and (hypo) manic
episode, in monthly assessments during the intervention
phase. Further secondary outcomes are (6) percentage of
assessments during intervention phase at which criteria
for an affective episode, defined by YMRS (> 12) and
IDS-30 (> 18) score are met and (7) average severity of
manic and depressive symptoms at assessments during
intervention phase. These criteria are estimated by total
YMRS and IDS-C30 scores at every assessment. Operatio-
nalization of the secondary outcomes (8) percentage of as-
sessments during intervention phase at which the patient
was hospitalized for an affective episode, and (9)
percentage of days during intervention phase at which the
patient was hospitalized for an affective episode, is
self-explanatory. (10) Number of adverse events is mea-
sured by the SAE (serious adverse event) reporting form
included in the electronic case report form (eCRF).
The outcome measures chosen in our trial are com-
monly used in similar long-term treatment trials in bipo-
lar disorders. In particular our primary endpoint, time to
new episode, is the most established endpoint in new
approval-seeking trials for psychopharmacological drugs
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our secondary endpoints will allow a better insight in
the robustness of our primary endpoint and in develop-
ing an understanding of the economic impact of our
intervention.
Study procedure
Inpatients and outpatients with bipolar disorder I/II
(currently symptomatic or stable) are assessed for eligi-
bility by experienced clinical staff working at the study
site who will present all relevant information about the
background, design, procedure, etc. of the study to the
patient and obtain informed consent in case of given eli-
gibility. After having signed informed consent, a pseudo-
nymized file is created for the patient in the electronic
database and the movisensXS smartphone application is
installed on a study smartphone handed over to the pa-
tient for his or her time of study participation, or, if
wished, on the patient’s own device. Participants continu-
ously receive open, guideline-based treatment for potential
current (hypo)manic and depressive symptomatology for
up to 20 weeks at the study sites outpatient clinics. As
soon as stabilisation criteria are met (Young Mania Rating
Scale total score < 12 and Inventory of Depressive Symp-
tomatology, clinician version total score < 18) during four
consecutive weeks, a baseline of the persons individual
smartphone usage pattern during euthymia is automat-
ically defined. Having fulfilled randomization criteria
(four consecutive weeks with YMRS total score < 12
and IDS-C30 total score < 18), patients are randomly
assigned to the Smartphone-Based Ambulatory Assess-
ment group, including real-time data capture and
data-driven therapeutic interventions (SBAA+), or to
the Smartphone-Based Ambulatory Assessment group,
only including real-time data capture (SBAA).
Randomization and blinding
A randomization list is stored in the electronic data-
base where all collected data is entered using eCRFs.
Based on this list, patients are allocated to the two
groups (SBAA resp. SBAA+) by block randomization,
stratified by age and type of bipolar disorder (I or II)
for every study site. Pseudonymized files are created in
the database for enrolled patients. The system allo-
cates patients to the groups corresponding to the
stored algorithm for randomization and the required
stratification factors. The patient and the assigned
psychiatrist are automatically and instantly informed
about which group (SBAA vs. SBAA+) the patient was
allocated to once randomization is carried out via the
database system. As regular ratings must not be biased
by group allocation knowledge, the observer/rater
remains blinded. Both treating psychiatrist and patient
are asked explicitly not to disclose any informationallowing conclusions regarding group allocation. As
the study psychiatrists are not blinded, there was no
need to provide special procedures for emergency
unblinding.
The intervention phase is planned for 18 months
(72 weeks). During this time, state-of-the-art treatment
of the bipolar condition continues for both groups. At-
tending psychiatrists will receive automatic feedback from
the movisensXS feedback server, every time the previously
calculated individual thresholds of patients in the SBAA+
group are significantly exceeded in any direction. A stan-
dardized procedure follows, where the psychiatrist con-
tacts the patient to assess, whether (a) the changes in
smartphone usage patterns can be explained by external
circumstances, or (b) show no hint for the beginning of a
new affective episode (false alarm), or (c) the changes
result from early signs of bipolar episodes. In this case
treatment options are discussed with the patient as in
regular guideline-based treatment. Additionally, in the
case that the rater detects an affective episode, the study
clinician will be informed so that thresholds can be chan-
ged towards more sensitivity if the patient is enrolled in
the intervention group and no automatic alarm has been
present.
On a monthly base, assessments of bipolar psychopath-
ology (SCID, YMRS, IDS-C30) are conducted by the rater
who is blind to the patients’ group assignment. A post-trial
follow-up of four weeks per patient follows subsequently
after the end of the 72 weeks intervention phase. Figure 2
shows the schematic study flow, serving as a detailed over-
view for the time schedule of enrolment, intervention,
assessment and visits for the participants.
The study population participants should be recruited
during 18 months, the first patient was enrolled in
January 2017.Statistical analysis
Confirmatory analysis
The primary objective (i.e. comparison of time to a new
episode under SBAA+ vs SBAA) will be addressed with
survival analysis. Kaplan-Meier plots will be used for esti-
mating the survival functions; a Log-Rank test will be used
to formally compare time to a new episode across treat-
ment groups. By using this strategy, the analysis will in-
clude data from all patients who were randomized (ITT
analysis). Although randomization will be used to attain
comparable conditions at baseline in both groups, im-
balances with respect to major confounders cannot be
completely ruled out. In this case, the predefined sur-
vival analyses will be backed up by a Cox-regression
which includes these confounders. All patients who
have been randomized will be included in the statistical
analyses.
Fig. 2 Study flow
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Regarding secondary endpoints, separate survival ana-
lyses will be applied according to the variables level of
measurement. For continuous endpoints, means and
standard deviations respectively medians and quartiles
are applied (graphically according to confidence inter-
vals respectively boxplots), for categorical endpoints
absolute and relative frequency are applied. Depending
on the distribution of the analyzed variables, a t-test,
U-test and Chi2-test are applied. For intraindividual
comparisons a paired t-test is applied for normally dis-
tributed variables, and a Wilcoxon-test for not normally
distributed variables.Access to the final trial dataset is granted to the spon-
sor who is the owner of all data. Access is also granted
to biometry staff.
Sample size calculation
Required sample size was calculated as in: n = 360 to
be assessed for eligibility; n = 180 to be allocated to
trial; n = 120 to be randomised to SBAA+ or SBAA;
n = 120 to be analysed. The sample size of n = 60 per
group was based on a power calculation for survival ana-
lysis with constant hazard and drop-out rates. This power
calculation requires specific assumptions regarding (a)
drop-out rate in SBAA (placebo), (b) global drop-out rate
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calculated with data from the psychiatric outpatient clinic,
as this population most closely corresponds to the exam-
ined sample. Accordingly we expect a monthly hazard rate
of 6%, which is equivalent to a relapse rate of 62% for the
course of the trial. From our experience with comparable
patients in similar studies we expect a drop-out rate of
approximately 2.5%. This is equivalent to a drop-out rate
of 26% for the course of the trial. A hazard ratio of 0.5 is
estimated, according to a reduction of the relapse rate
from 62 to 41% in the intervention group. This assump-
tion is consistent with results of a Cochrane review on
interventions, helping patients to identify early warning
signs. The hazard ratio of 0.5 equals the median hazard ra-
tio in studies, which compare TAU and TAU plus detec-
tion of EWS for relapse. This estimation is considered
rather conservative as smartphone usage in this trial
expectedly leads to a quicker and more reliable detection
of warning signs, thus we expect a greater effect com-
pared to the studies mentioned. Hence, with 81% this
trial is sufficiently powered to demonstrate the advan-
tage of SBAA+ compared to SBAA regarding the primary
outcome (α = .05, one-tailed). Power calculation was per-
formed using SAS software, version 9.3 (2011, Cary, NC).
Discussion
This article describes the design of a clinical trial investigat-
ing the effectiveness of a smartphone based feedback loop
eliciting early interventions at the detection of warning
signs for the prevention of depressive and manic states in
bipolar patients. As a result of this trial and the data ob-
tained new passive, non-invasive monitoring solutions will
be better supported in the future. The medium-term
objective is the development of applications which help
optimize the timing of suitable interventions in bipolar
patients without substantial active involvement of the pa-
tients themselves. This approach will hopefully improve the
chances of a timely intervention that helps patients to keep
a balanced mood for longer periods of time as well as con-
tribute to a higher level of functioning and quality of life.
Strengths and limitations
This study uses new and widely spread smartphone
technology for the further improvement of the long
term treatment of patients with bipolar disorder. Using
a smartphone application to monitor everyday commu-
nication and activity could operationalize changes in
affective states. This approach is non-invasive, requires pa-
tients’ minimal effort and, if proven effective, will be a
cost-effective and promising solution to help people with
bipolar disorder to spend less time in affective episodes.
With a total duration of 21 months the presented study
comprises a comparatively long period of time of continu-
ous ambulatory assessment. The 18-month interventionphase allows for a strong data basis for analyzing the
effectiveness of the described feedback algorithm. Limita-
tions of this trial might concern the representability of the
sample, as some patients cannot participate. This includes
patients who want to use their own iPhone (movisensXS
only available for Android) and women with an acute
desire to have children. Due to technical limitations, use
duration of common communication apps (WhatsApp,
Facebook Messenger …) could not be monitored from the
beginning of the trial and therefore this data is not in-
cluded in the feedback algorithm.
Trial status
Recruitment and enrollment of the first patient started
in January 2017.
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